# Phase 5 Blocking Items Assessment & Dependency Analysis
**Date**: April 10, 2026  
**Prepared By**: Project Management  
**Purpose**: Identify any items that could block Phase 5 start (June 10)

---

## 📋 Phase 5 Overview

**Start Date**: June 10, 2026  
**Duration**: 2 weeks (Jun 10-24)  
**Deliverables**: Feature completeness validation  
**Success Gate**: 100% feature completeness OR documented roadmap for Phase 6

---

## 🔍 Dependency Analysis: What Must Be Complete for Phase 5?

### ✅ **MUST COMPLETE (Blocking if not done)**

#### Dependency 1: Phase 3 Production Approval ✅
**Status**: ✅ DONE (Apr 10)
- All sign-offs collected
- 0 critical vulnerabilities
- Production-approved
- **Blocking Risk**: NONE (complete)

#### Dependency 2: Phase 4 Performance Optimization ⏳
**Status**: IN PROGRESS (May 13-Jun 3)
- **Must meet gates**: <500ms p95, <1% error rate
- **Acceptance**: All 4 weekly gates pass
- **If not met**: Need remediation plan before Phase 5
- **Blocking Risk**: MEDIUM (depends on Phase 4 success)
- **Mitigation**: Weekly gate reviews; escalate blockers immediately

#### Dependency 3: Phase 2 Test Coverage ⏳
**Status**: IN PROGRESS (targeting >70% by May 10)
- **Current**: ~55-60%
- **Target**: >70% by Phase 4 kickoff (May 13)
- **If not met**: Phase 4 execution risk increases
- **Blocking Risk**: LOW (non-blocking, but reduces confidence)
- **Mitigation**: QA track coverage improvement in parallel

#### Dependency 4: Phase 1 Code Quality ⏳
**Status**: IN PROGRESS
- **Current**: 40% HP refactoring
- **Target**: Minimum 65%+ by Phase 5
- **If not met**: Code review delays in Phase 5
- **Blocking Risk**: LOW (affects velocity, not blocking)
- **Mitigation**: Parallel with Phase 4

---

## ⚠️ **POTENTIAL BLOCKING ITEMS FOR PHASE 5**

### Issue 1: Incomplete Phase 4 Optimization
**Risk Level**: MEDIUM  
**Impact**: Phase 5 starts with poor system performance  
**Likelihood**: Medium (depends on real-world results)

**Mitigation**:
- [ ] Weekly gate reviews starting May 13
- [ ] Escalation protocol for blockers
- [ ] Contingency: Extended Phase 4 if necessary
- [ ] Decision: Can Phase 5 proceed with partial optimization?

**Action**:
- If <3 gates pass (out of 4 weekly): Phase 5 delayed 1 week
- If all gates pass: Phase 5 starts as planned Jun 10

---

### Issue 2: Feature Gap Analysis Not Complete
**Risk Level**: MEDIUM  
**Impact**: Phase 5 lacks clear feature roadmap  
**Likelihood**: Low (can be done in parallel)

**Mitigation**:
- [ ] Start feature gap analysis in May (Week 14)
- [ ] Have prioritized list by Jun 3 (Phase 4 end)
- [ ] Identify "must-have" vs "should-have" vs "nice-to-have"

**Action**:
- Complete gap analysis by Phase 4 completion (Jun 3)
- If not done: Phase 5 delayed 3 days for planning

---

### Issue 3: Clinical Workflow Validation Gaps
**Risk Level**: MEDIUM  
**Impact**: Patient safety issues discovered late  
**Likelihood**: Low (Phase 3 validated extensively)

**Mitigation**:
- [ ] Involve Clinical Lead in Phase 5 planning now
- [ ] Identify remaining validation gaps
- [ ] Schedule clinical UAT in Phase 5 (weeks 1-2)

**Action**:
- Get clinical sign-off on Phase 5 scope before Jun 10
- If not aligned: Phase 5 delayed for alignment

---

### Issue 4: Infrastructure Capacity Concerns
**Risk Level**: LOW  
**Impact**: System can't handle production load  
**Likelihood**: Very low (Phase 4 tests extensively)

**Mitigation**:
- [ ] Phase 4 Week 16 load test validates capacity
- [ ] If capacity issues found: Quick fix or delay Phase 5
- [ ] Have rollback plan ready

**Action**:
- Load test must pass by Jun 3
- If capacity gaps: Emergency optimization sprint Jun 4-9
- If not fixable: Phase 5 delayed until resolved

---

## 📝 Feature Gap Analysis Checklist

**Identified Categories** (to assess in May):

### Core Clinical Features (Assess Impact)
- [ ] Advanced analytics/dashboards
- [ ] Predictive alerts
- [ ] Mobile app support
- [ ] Telemedicine integration
- [ ] Prescription refill automation
- [ ] Insurance pre-authorization workflow
- [ ] Radiology PACS integration
- [ ] EMR/EHR integration

### Admin Features (Assess Impact)
- [ ] Multi-hospital reporting
- [ ] User role customization
- [ ] Audit trail advanced search
- [ ] Performance analytics dashboard
- [ ] Cost analysis tools
- [ ] Capacity planning tools

### Security/Compliance Features (Assess Impact)
- [ ] GDPR data export
- [ ] Right-to-be-forgotten implementation
- [ ] Advanced encryption options
- [ ] Biometric authentication
- [ ] Blockchain audit trail logging

**Task**: Categorize each as Must-Have (Phase 5) vs Should-Have (Phase 6) vs Nice-to-Have (Future)

---

## 🚀 Pre-Phase 5 Readiness Checklist

**Due: June 10, 2026**

### Technical Readiness
- [ ] Phase 4 all gates passed (4/4 weekly gates ✅)
- [ ] <500ms p95 achieved
- [ ] <1% error rate confirmed
- [ ] 10-pod K8s scaling validated
- [ ] Load test metrics captured
- [ ] Performance baseline documented

### Feature Readiness
- [ ] Feature gap analysis complete
- [ ] Gaps prioritized (Must/Should/Nice)
- [ ] Phase 5 scope defined
- [ ] Phase 5 sprint planned
- [ ] User stories written for gaps

### Clinical Readiness
- [ ] Clinical Lead reviewed Phase 5 scope
- [ ] Patient safety impact assessed
- [ ] UAT plan confirmed
- [ ] Clinical sign-off obtained

### Team Readiness
- [ ] Phase 4 retrospective completed
- [ ] Lessons learned documented
- [ ] Phase 5 team assigned
- [ ] Phase 5 sprint board created
- [ ] Communication cadence confirmed

### Documentation Readiness
- [ ] Phase 4 completion report filed
- [ ] Performance metrics captured for baseline
- [ ] Architecture updates documented
- [ ] Deployment notes updated

---

## ✅ **GO / NO-GO DECISION FRAMEWORK**

**Phase 5 Start Decision** (Due: June 9, 2026)

**GO Decision** (Phase 5 starts Jun 10):
- ✅ Phase 4 Week 16 all gates passed
- ✅ <500ms p95 threshold met
- ✅ <1% error rate confirmed
- ✅ Feature gap analysis complete
- ✅ Phase 5 scope approved by CTO
- ✅ Clinical sign-off obtained
- ✅ Team ready to execute

**NO-GO Decision** (Phase 5 delayed):
- ❌ Phase 4 blockers unresolved (performance not met)
- ❌ Feature gap analysis incomplete
- ❌ Clinical concerns unaddressed
- ❌ Team not ready
- **Remediation**: Identify gap + create fix plan + restart timer

**CONDITIONAL-GO** (Phase 5 starts with constraints):
- ⚠️ Minor Phase 4 issues unresolved
- ⚠️ Partial feature gap analysis
- **Constraints**: Specific items added to Phase 5 sprint
- **Risk**: Documented and accepted by CTO

---

## 🎯 Blocking Items Summary Table

| Item | Category | Risk | Mitigation | Owner | Status |
|------|----------|------|-----------|-------|--------|
| Phase 4 performance gates | Technical | MEDIUM | Weekly reviews + escalation | DevOps Lead | ⏳ May 13-Jun 3 |
| Phase 2 test coverage | Technical | LOW | QA parallel work | QA Lead | ⏳ May 1-10 |
| Feature gap analysis | Planning | MEDIUM | Start in May | Project Lead | 📅 May 13-Jun 3 |
| Clinical alignment | Clinical | MEDIUM | Early engagement | Clinical Lead | 📅 May 1-Jun 9 |
| Infrastructure capacity | Technical | LOW | Load test Jun 3 | DevOps Lead | ⏳ Jun 3 |

---

## 📅 Critical Timeline for Phase 5 Readiness

```
May 1-10:      Phase 2 coverage improvement (parallel)
May 1-12:      Clinical Lead alignment on Phase 5 scope
May 13-Jun 3:  Phase 4 execution (gates reviewed weekly)
Jun 1-9:       Feature gap analysis finalization
Jun 9 EOD:     GO/NO-GO decision for Phase 5
Jun 10:        Phase 5 starts (if approved)
```

---

## 🚨 Risk Mitigation Strategies

**If Phase 4 Blocks Occur**:
1. Immediate escalation to CTO
2. Emergency 2-4 hour fix window
3. If not fixed: Delay Phase 5 by 1 week
4. Extended Phase 4 sprint to resolve

**If Feature Gap Analysis Shows Too Many Gaps**:
1. Prioritize must-haves only for Phase 5
2. Move should-haves/nice-to-haves to Phase 6
3. Replan Phase 5 with reduced scope
4. Maintain quality over speed

**If Clinical Concerns Emerge**:
1. Clinical Lead + Project Lead sync immediately
2. Assess severity (path-blocking vs Phase-6 item?)
3. Add safety validation to Phase 5 if needed
4. Maintain patient safety as top priority

---

## 📞 Phase 5 Readiness Points of Contact

**Technical Blockers**: DevOps Lead → CTO  
**Feature Scope**: Project Lead → CTO  
**Clinical Alignment**: Clinical Lead → CTO  
**Timeline/Go-Live**: Project Lead → CTO  
**Executive Decision**: CTO (final authority)

---

## ✅ Blocking Items Assessment: COMPLETE

**Overall Risk**: MEDIUM (depends on Phase 4 success)  
**Confidence**: HIGH (dependencies clear, mitigations in place)  
**Go/No-Go**: Ready to assess June 9 at scheduled gate

**Recommendation**: No blocking items identified that prevent Phase 5 planning to proceed. Phase 4 execution is critical path. Weekly gate reviews will reveal any issues early.

---

**Assessment Prepared**: April 10, 2026  
**Valid Through**: June 3, 2026  
**Next Review**: Weekly (Fridays during Phase 4)  
**Final Decision**: June 9, 2026 (GO/NO-GO for Phase 5)

